WRBY vs. BLCO, RXST, STAA, EYE, LUCY, ALC, COO, ENSG, MASI, and JAZZ
Should you be buying Warby Parker stock or one of its competitors? The main competitors of Warby Parker include Bausch + Lomb (BLCO), RxSight (RXST), STAAR Surgical (STAA), National Vision (EYE), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), The Ensign Group (ENSG), Masimo (MASI), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "medical" sector.
Warby Parker (NYSE:WRBY) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Warby Parker has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
In the previous week, Warby Parker and Warby Parker both had 6 articles in the media. Bausch + Lomb's average media sentiment score of 0.74 beat Warby Parker's score of 0.57 indicating that Bausch + Lomb is being referred to more favorably in the news media.
Bausch + Lomb has a net margin of -7.81% compared to Warby Parker's net margin of -7.89%. Bausch + Lomb's return on equity of 3.60% beat Warby Parker's return on equity.
93.2% of Warby Parker shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 26.6% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Warby Parker presently has a consensus price target of $16.50, indicating a potential downside of 6.83%. Bausch + Lomb has a consensus price target of $19.45, indicating a potential upside of 26.82%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Warby Parker.
Warby Parker has higher earnings, but lower revenue than Bausch + Lomb. Warby Parker is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
Warby Parker and Bausch + Lomb both received 24 outperform votes by MarketBeat users. However, 38.71% of users gave Bausch + Lomb an outperform vote while only 32.88% of users gave Warby Parker an outperform vote.
Summary
Bausch + Lomb beats Warby Parker on 10 of the 16 factors compared between the two stocks.
Get Warby Parker News Delivered to You Automatically
Sign up to receive the latest news and ratings for WRBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WRBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warby Parker Competitors List
Related Companies and Tools
